Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2026-01-09 | 2026-01-09 |
| Drug Identification Number | 02525852 | 02525852 |
| Brand name | BYOOVIZ | BYOOVIZ |
| Common or Proper name | BYOOVIZ | BYOOVIZ |
| Company Name | SAMSUNG BIOEPIS CO., LTD | SAMSUNG BIOEPIS CO., LTD |
| Ingredients | RANIBIZUMAB | RANIBIZUMAB |
| Strength(s) | 10MG | 10MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVITREAL | INTRAVITREAL |
| Packaging size | Vial + filter needle + injection needle pack & Vial only pack | Vial + filter needle + injection needle pack & Vial only pack |
| Additional packaging sizes | ||
| ATC code | S01LA | S01LA |
| ATC description | OCULAR VASCULAR DISORDER AGENTS | OCULAR VASCULAR DISORDER AGENTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2026-01-01 | 2026-01-01 |
| Estimated end date | 2026-06-30 | 2026-06-30 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | The current shortage arises from the delay of contract with new partner followed by the delay in preparing the new supply under the new brand name. | The current shortage arises from the delay of contract with new partner followed by the delay in preparing the new supply under the new brand name. |
| Health Canada comments |